-
Rituximab, sold
under the
brand name
Rituxan among others, is a
monoclonal antibody medication used to
treat certain autoimmune diseases and
types of...
-
antibodies such as
rituximab,
which are
increasingly being used as first-line treatment. In
summer 2018, the FDA
granted full
approval to
rituximab for this application...
- of t-FL (e.g., the
addition to
standard chemotherapy of
agents such as
rituximab) have
improved overall survival times.
These newer regimens may also delay...
- 90% to less than 20%. Immunosuppressants, such as glucocorticoids, and
rituximab may also be used.
Platelet transfusions are
generally not recommended...
- use corticosteroids.[citation needed] The anti-CD20
monoclonal antibody rituximab has been
found to be
effective in
treating some
otherwise refractory cases...
-
bendamustine with
rituximab.
Second line
treatment may
include fludarabine,
combined with
cyclophosphamide and/or mitoxantrone,
usually with
rituximab. Cladribine...
-
corticosteroid and
immunomodulator treatments are not sufficient,
rituximab may also be used.
Rituximab has been
shown to
induce and
maintain remission. AIP does...
- (more than 3
years if
combined with
rituximab),
after which remission occurs. BRAF
inhibitors with or
without rituximab may be
restarted if
there is relapsed...
- as
rituximab or
cyclophosphamide and high-dose
corticosteroids to
control the
symptoms of the
disease and azathioprine, methotrexate, or
rituximab to...
- (MCL), with or
without prior rituximab-containing
chemoimmunotherapy treatment, is
bendamustine with
mitoxantrone and
rituximab. In
Germany in 2012 it has...
